PRODUCTION PLANT
Curitiba (Parana)
The R2 IBF plant in Curitiba was inaugurated in 2012, after obtaining marketing authorization by the Brazilian Health Regulatory Agency (ANVISA), the National Commission for Nuclear Energy (CNEN) and other regulatory agencies.
From the beginning, the main objective of our plant is to supply the Cyclofluor ® radiopharmaceutical (FDG (18 F)) to clinics and hospitals in Brazil. For this, we have a highly qualified multidisciplinary technical team and modern equipment that allow the accomplishment of up to three daily batches of the radiopharmaceutical, thus increasing the distribution capacity of our product.
Our mission
We work to providing exceptional outcomes to our customers and their patients.
Focus
To develop, manufacture and supply high quality radiopharmaceutical products to our customers.
Always support the growth of nuclear medicine in Brazil, offering new products with excellence.
Ethics & Responsibility
We respect our partners and our customers.
We understand its importance in the present and future of our company.
We have responsibility with our collaborators, our community, our country; therefore, we work with a focus on ethics and commitment to the development of the people and the environment in which we are inserted.
PRODUCT
Curitiba (Parana)
CYCLOFLUOR®
fludesoxyglucose (18 F)
The Cyclofluor® (fludesoxyglucose (18 F)) is a radiopharmaceutical used in Positron Emission Tomography (PET-CT), in nuclear medicine, with applications in cardiology, neurology, and especially in oncology. The use of FDG (18 F) in PET-CT studies is especially important because it allows a metabolic evaluation related to the body's glucose consumption, which gives it a prominent role in the diagnosis and staging of the tumor, as well as in the early evaluation of efficacy of the therapeutic protocols adopted in patients with certain types of cancer, being determinant in the medical clinical conduct to be applied.
TECNOLOGIA
Curitiba (Parana)
The Curitiba plant has a 16.5 MeV, PETtrace 880 model, particle accelerator (cyclotron) manufactured by GE Healhtcare; equipment used in the manufacture of ultra short half-life radioisotopes, mainly fluorine-8 (18F). A particularity of Curitiba's particle accelerator is that it is the only GE self-shielded in the country, which maintains the same efficiency in terms of radiological shielding compared to bunker accelerators but masonry shielding (building construction) more compact.
GE's FASTlab synthesis modules, responsible for producing the FDG (18 F) radiopharmaceutical, have their entire process automated and yield up to 70%. The Cyclopet has two of these modules, which guarantees up to two syntheses per day, allowing continuous production with high performance and reliability.
QUALIDADE E MELHORIA CONTÍNUA
Curitiba (Parana)
COMMITMENT TO QUALITY. FOCUS ON CONTINUOUS IMPROVEMENT.
Established in August 2019, R2 IBF focuses on developing, producing and supplying quality radiopharmaceuticals to our customers and supporting the growth of nuclear medicine in Brazil. For this we have three production plants, strategically located in the cities of Porto Alegre (Rio Grande do Sul), Curitiba (Parana) and Sao Jose do Rio Preto (Sao Paulo) and, soon, we will start the routine production of the most modern radiopharmaceutical plant in Brazil, in Duque de Caxias (Rio de Janeiro). Together, the plants result in an excellent production capacity, about 50Ci of FDG per fludesoxyglucose (18 F) radiopharmaceutical production batch. This structure gives our customers and partners greater peace of mind and security in the daily receiving of the drug by establishing safer and more efficient logistics, as well as the back-up supply system required during preventive and corrective maintenance periods.
Still, in a pioneering way, the R2 IBF became the first private company in the Brazilian industry to form a group of research, development and innovation for new radiopharmaceuticals, thereby hope to soon increase its portfolio with new radiopharmaceuticals, including:
18F-PSMA-1007: for prostate cancer diagnosis - tumor localization in recurrent prostate cancer; initial staging in patients with high-risk prostate cancer before surgical planning or radiotherapy; PSMA PET-guided biopsy after a negative biopsy; monitoring of systemic treatment in metastatic prostate cancer.
18F-Flutemetamol: used for PET imaging to assess the density of β-amyloid plaques in the cerebral parenchyma of patients with cognitive decline, whether suspected of dementia due to Alzheimer's disease or other suspected dementias.
We understand that our customers and partners are very important for our development, so we work with focus on ethics and commitment to the development of people and the environment in which we operate.
R2IBF - Curitiba-PR
Rua Cezinando Dias Paredes 367
Curitiba - PR CEP 81730-090
Tel: +55 41 3153 3106
